Vitamin D 3 5000 Iu

Vitamin D 3 5000 Iu

Randomized Controlled Trial

. 2021 Jun 24;13(7):2170.

doi: 10.3390/nu13072170.

Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial

Mushira A Enani 2 , Eman Sheshah 3 , Naji J Aljohani 1 4 , Dara A Aldisi 5 , Naif H Alotaibi 6 , Naemah Alshingetti 7 , Suliman Y Alomar 8 , Abdullah M Alnaami 1 , Osama E Amer 1 , Syed D Hussain 1 , Nasser M Al-Daghri 1

Affiliations

  • PMID: 34202578
  • PMCID: PMC8308273
  • DOI: 10.3390/nu13072170

Free PMC article

Randomized Controlled Trial

Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial

Shaun Sabico  et al. Nutrients. .

Free PMC article

Abstract

Objective: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19 patients with sub-optimal vitamin D status.

Study design and setting: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000 IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery.

Results: Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan-Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035).

Conclusion: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.

Keywords: COVID-19; clinical trial; saudi; vitamin D; vitamin D insufficiency.

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1

Flowchart of participants.

Figure 2
Figure 2

Unadjusted Kaplan–Meier Plot showing the recovery times for cough (A) and ageusia (B) according to vitamin D dose.

Figure 3
Figure 3

Mean 25(OH) D concentration before and after supplementation.

Similar articles

  • Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.

    Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, Macedo MB, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ, Antonangelo L, Caparbo VF, Gualano B, Pereira RMR. Murai IH, et al. JAMA. 2021 Mar 16;325(11):1053-1060. doi: 10.1001/jama.2020.26848. JAMA. 2021. PMID: 33595634 Free PMC article. Clinical Trial.

  • Vitamin D supplementation for sickle cell disease.

    Soe HHK, Abas AB, Than NN, Ni H, Singh J, Said ARBM, Osunkwo I. Soe HHK, et al. Cochrane Database Syst Rev. 2020 May 28;5(5):CD010858. doi: 10.1002/14651858.CD010858.pub3. Cochrane Database Syst Rev. 2020. PMID: 32462740 Free PMC article.

  • Vitamin D3 supplementation, low-risk prostate cancer, and health disparities.

    Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Hollis BW, et al. J Steroid Biochem Mol Biol. 2013 Jul;136:233-7. doi: 10.1016/j.jsbmb.2012.11.012. Epub 2012 Dec 7. J Steroid Biochem Mol Biol. 2013. PMID: 23220550 Review.

  • Changes in 25-hydroxyvitamin D levels post-vitamin D supplementation in people of Black and Asian ethnicities and its implications during COVID-19 pandemic: A systematic review.

    Vaughan M, Trott M, Sapkota R, Premi G, Roberts J, Ubhi J, Smith L, Pardhan S. Vaughan M, et al. J Hum Nutr Diet. 2021 Oct 6. doi: 10.1111/jhn.12949. Online ahead of print. J Hum Nutr Diet. 2021. PMID: 34617343 Review.

Cited by 7 articles

  • Modifiable Risk Factors for SARS-CoV-2.

    Simon M, Pizzorno J, Katzinger J. Simon M, et al. Integr Med (Encinitas). 2021 Oct;20(5):8-14. Integr Med (Encinitas). 2021. PMID: 34803534 Free PMC article.

  • Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.

    Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Farahani M, et al. Biomed Pharmacother. 2021 Nov 12;145:112420. doi: 10.1016/j.biopha.2021.112420. Online ahead of print. Biomed Pharmacother. 2021. PMID: 34801852 Free PMC article. Review.

  • Consumption of Food Supplements during the Three COVID-19 Waves in Poland-Focus on Zinc and Vitamin D.

    Puścion-Jakubik A, Bielecka J, Grabia M, Mielech A, Markiewicz-Żukowska R, Mielcarek K, Moskwa J, Naliwajko SK, Soroczyńska J, Gromkowska-Kępka KJ, Nowakowski P, Socha K. Puścion-Jakubik A, et al. Nutrients. 2021 Sep 25;13(10):3361. doi: 10.3390/nu13103361. Nutrients. 2021. PMID: 34684363 Free PMC article.

  • Predictors of Mental Health Status among Quarantined COVID-19 Patients in Saudi Arabia.

    Alodhayani AA, Almutairi KM, Alshobaili FA, Alotaibi AF, Alkhaldi G, Vinluan JM, Albedewi HM, Al-Sayyari L. Alodhayani AA, et al. Healthcare (Basel). 2021 Sep 26;9(10):1271. doi: 10.3390/healthcare9101271. Healthcare (Basel). 2021. PMID: 34682951 Free PMC article.

  • Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19.

    Nakano T, Chiang KC, Chen CC, Chen PJ, Lai CY, Hsu LW, Ohmori N, Goto T, Chen CL, Goto S. Nakano T, et al. Int J Environ Res Public Health. 2021 Oct 18;18(20):10950. doi: 10.3390/ijerph182010950. Int J Environ Res Public Health. 2021. PMID: 34682694 Free PMC article. Review.

References

    1. Dong E., Du H., Gardner L. An Interactive Web-Based Dashboard to Track COVID-19 in Real Time. Lancet Infect. Dis. 2020;20:533–534. doi: 10.1016/S1473-3099(20)30120-1. - DOI - PMC - PubMed
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536–544. doi: 10.1038/s41564-020-0695-z. - DOI - PMC - PubMed
    1. Oran D.P., Topol E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann. Intern. Med. 2020;173:362–367. doi: 10.7326/M20-3012. - DOI - PMC - PubMed
    1. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) JAMA. 2020;323:1824–1836. doi: 10.1001/jama.2020.6019. - DOI - PubMed
    1. Lancet T. COVID-19 Vaccines: No Time for Complacency. Lancet. 2020;396:1607. doi: 10.1016/S0140-6736(20)32472-7. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

  • Full Text Sources

    • Europe PubMed Central
    • Multidisciplinary Digital Publishing Institute (MDPI)
    • PubMed Central
  • Medical

    • MedlinePlus Health Information
  • Miscellaneous

    • NCI CPTAC Assay Portal

Vitamin D 3 5000 Iu

Source: https://pubmed.ncbi.nlm.nih.gov/34202578/

Share:

Tidak ada komentar:

Posting Komentar

Recent Posts

banner